MRK Stock Overview
Merck KGaA operates as a science and technology company in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €154.20 |
| 52 Week High | €179.50 |
| 52 Week Low | €154.20 |
| Beta | 0.58 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -7.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRK | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | 3.6% | 0.2% |
| 1Y | -7.1% | 8.9% | 17.0% |
Return vs Industry: MRK underperformed the BG Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: MRK underperformed the BG Market which returned 10.8% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BG Market | 8.5% |
| 10% least volatile stocks in BG Market | 2.4% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MRK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 63,712 | Belen Garijo Lopez | www.emdgroup.com |
Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines.
Merck KGaA Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | €71.96b |
| Earnings (TTM) | €3.08b |
| Revenue (TTM) | €22.06b |
23.4x
P/E Ratio3.3x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | €22.06b |
| Cost of Revenue | €8.51b |
| Gross Profit | €13.55b |
| Other Expenses | €10.47b |
| Earnings | €3.08b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 09, 2023
| Earnings per share (EPS) | 7.08 |
| Gross Margin | 61.43% |
| Net Profit Margin | 13.95% |
| Debt/Equity Ratio | 40.0% |
How did MRK perform over the long term?
See historical performance and comparison